Last reviewed · How we verify
SL fentanyl
At a glance
| Generic name | SL fentanyl |
|---|---|
| Also known as | Abstral |
| Sponsor | Orexo AB |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Impact of Sublingual Sufentanil on Postoperative Pain and Analgesic Requirements in Spine Surgery Patients (PHASE4)
- Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement (NA)
- Sublingual Fentanyl for the Management of Breakthrough Pain (PHASE2)
- Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea (PHASE2, PHASE3)
- Conversion From Fast Acting Oral Opioids to Abstral® (PHASE4)
- Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain (PHASE3)
- Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain (PHASE3)
- Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |